| Literature DB >> 29775790 |
Melek Simsek1, Berrie Meijer2, Dewkoemar Ramsoekh2, Gerd Bouma2, Egbert-Jan van der Wouden3, Bert den Hartog4, Annemarie C de Vries5, Frank Hoentjen6, Gerard Dijkstra7, Sybrand Y de Boer8, Jeroen M Jansen9, Andrea E van der Meulen10, Ruud Beukers11, Menno A Brink12, Toos Steinhauser13, Bas Oldenburg14, Lennard P Gilissen15, Ton H Naber16, Marc A Verhagen17, Nanne K H de Boer2, Chris J J Mulder2.
Abstract
Nodular regenerative hyperplasia (NRH) is a poorly understood liver condition, which is increasingly recognized in thiopurine-treated patients with inflammatory bowel disease (IBD).1 It is difficult to establish an optimal approach to NRH patients, because its manifestations are highly variable (from asymptomatic to symptoms of noncirrhotic portal hypertension [NCPH]) and the prognosis is unknown.2 The aim of this study was to identify NRH cases in IBD patients treated with azathioprine, mercaptopurine, and/or thioguanine, and to describe its clinical course.Entities:
Mesh：
Substances：
Year: 2018 PMID： 29775790 DOI： 10.1016/j.cgh.2018.05.009
Source DB: PubMed Journal: Clin Gastroenterol Hepatol ISSN： 1542-3565 Impact factor: 11.382